Mifamurtide (CAS 83461-56-7)
Alternate Names:
Muramyl tripeptide phosphatidylethanolamine; N-(N-Acetylmuramoyl)-L-alanyl-D-alpha-glutaminyl-N-[(7R)-4-hydroxy-4-oxido-10-oxo-7-[(1-oxohexadecyl)oxy]-3,5,9-trioxa-4-phosphapentacos-1-yl]-L-alaninamide
CAS Number:
83461-56-7
Molecular Weight:
1237.50
Molecular Formula:
C59H109N6O19P
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Mifamurtide is a liposomal formulation that contains an analog of muramyl dipeptide (MDP) with potential immunomodulatory and antineoplastic effects. Muramyl tripeptide phosphatidylethanolamine (MTP-PE), which is a derivative of MDP found in the mycobacterial cell wall, can activate monocytes and macrophages. Activated macrophages can secrete cytokines and induce the recruitment and activation of other immune cells, which may result in indirect antitumor effects. The use of liposomal encapsulation to deliver MTP-PE can increase its half-life and enhance its tissue targeting.
Mifamurtide (CAS 83461-56-7) References
- Mifamurtide: CGP 19835, CGP 19835A, L-MTP-PE, liposomal MTP-PE, MLV 19835A, MTP-PE, muramyltripeptide phosphatidylethanolamine. | . 2008. Drugs R D. 9: 131-5. PMID: 18298131
- Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma. | Meyers, PA. 2009. Expert Rev Anticancer Ther. 9: 1035-49. PMID: 19671023
- Mifamurtide: a review of its use in the treatment of osteosarcoma. | Frampton, JE. 2010. Paediatr Drugs. 12: 141-53. PMID: 20481644
- Mifamurtide in osteosarcoma--a practical review. | Anderson, PM., et al. 2010. Drugs Today (Barc). 46: 327-37. PMID: 20517534
- Mifamurtide for the treatment of nonmetastatic osteosarcoma. | Ando, K., et al. 2011. Expert Opin Pharmacother. 12: 285-92. PMID: 21226638
- Mifamurtide: osteosarcoma: ineffective and harmful. | . 2011. Prescrire Int. 20: 89. PMID: 21648206
- Mifamurtide for high-grade, resectable, nonmetastatic osteosarcoma following surgical resection: a cost-effectiveness analysis. | Johal, S., et al. 2013. Value Health. 16: 1123-32. PMID: 24326165
- Economic Considerations On the Use of Mifamurtide In the Treatment of Osteosarcoma In Spain. | Brosa, M., et al. 2014. Value Health. 17: A526-7. PMID: 27201662
- The Role of Mifamurtide in Chemotherapy-induced Osteoporosis of Children with Osteosarcoma. | Bellini, G., et al. 2017. Curr Cancer Drug Targets. 17: 650-656. PMID: 27993113
- Mifamurtide and TAM-like macrophages: effect on proliferation, migration and differentiation of osteosarcoma cells. | Punzo, F., et al. 2020. Oncotarget. 11: 687-698. PMID: 32133045
- Muramyl Tripeptide Plus Chemotherapy Reduces Metastasis in Non-Metastatic Osteosarcoma: A Single-Center Experience. | Taçyıldız, N., et al. 2020. Asian Pac J Cancer Prev. 21: 715-720. PMID: 32212798
- Type 4 hypersensitivity development in a case due to mifamurtide. | Şimşek, M., et al. 2020. Turk J Pediatr. 62: 694-699. PMID: 32779428
- The perplexing role of immuno-oncology drugs in osteosarcoma. | Smrke, A., et al. 2021. J Bone Oncol. 31: 100400. PMID: 34786332
- Gut microbial DL-endopeptidase alleviates Crohn's disease via the NOD2 pathway. | Gao, J., et al. 2022. Cell Host Microbe. 30: 1435-1449.e9. PMID: 36049483
- Microbe-mediated intestinal NOD2 stimulation improves linear growth of undernourished infant mice. | Schwarzer, M., et al. 2023. Science. 379: 826-833. PMID: 36821686
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Mifamurtide, 100 µg | sc-481153 | 100 µg | $520.00 | |||
Mifamurtide, 1 mg | sc-481153B | 1 mg | $1072.00 | |||
Mifamurtide, 2 mg | sc-481153C | 2 mg | $1693.00 | |||
Mifamurtide, 5 mg | sc-481153D | 5 mg | $1948.00 |